Table 2. Immunogenicity test results of the study participants.

Characteristics			Neutralizing antibody test results	Anti-S antibody test results	SARS CoV-2 IgG test results
Participants who received at least the first 2 doses of the vaccine (n=10,848)
	Baseline
		Positive	3,095 (28.8)	3,260 (30.3)
		Negative	7,668 (71.2)	7,503 (69.7)
		No test	85	85
	Day 35
		Positive	8,189 (96.6)	8,001 (96.3)	6 (22.2)
		Negative	291 (3.4)	309 (3.7)	21 (77.8)
		No test/follow-up	2,368	2,538	10,821
	Day 180
		Positive	3,821 (70.6)	3,863 (71.5)	2,057 (38.2)
		Negative	1,593 (29.4)	1,541 (28.5)	3,328 (61.8)
		No test/follow-up	5,434	5,444	5,463
	Day 194
		Positive	2,722 (95.9)	2,716 (96.0)	2,097 (74.3)
		Negative	115 (4.1)	112 (4.0)	724 (25.7)
		No test/follow-up	8,011	8,020	8,027
	Day 360
		Positive	1,716 (96.2)	1,721 (96.5)	1,306 (73.3)
		Negative	68 (3.8)	62 (3.5)	476 (26.7)
		No test/follow-up	9,064	9,065	9,066
Participants who received the first 2 doses and the booster dose of the vaccine (n=5,050)
	Baseline
		Positive	1,611 (32.2)	1,696 (33.9)
		Negative	3,394 (67.8)	3,309 (66.1)
		No test	45	45
	Day 35
		Positive	4,270 (97.4)	4,172 (96.4)	1 (20.0)
		Negative	113 (2.6)	158 (3.6)	4 (80.0)
		No test/follow-up	667	720	5,045
	Day 180
		Positive	3,411 (71.8)	3,457 (72.8)	1,849 (39.1)
		Negative	1,340 (28.2)	1,293 (27.2)	2,878 (60.9)
		No test/follow-up	299	300	323
	Day 194
		Positive	2,582 (98.7)	2,575 (98.5)	2,023 (77.8)
		Negative	35 (1.3)	40 (1.5)	576 (22.2)
		No test/follow-up	2,433	2,435	2,451
	Day 360
		Positive	1,715 (96.2)	1,721 (96.5)	1,306 (73.3)
		Negative	68 (3.8)	62 (3.5)	476 (26.7)
		No test/follow-up	3,267	3,267	3,268

Values are presented as number (%).

SARS CoV-2, severe acute respiratory syndrome coronavirus 2; IgG, immunoglobulin G.